MICHAEL GEORGE AMAN

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi request reprint Outcome measures for clinical drug trials in autism
    Michael G Aman
    Department of Psychology, Nisonger Center, Ohio State University, Columbus 43210 1257, USA
    CNS Spectr 9:36-47. 2004
  2. ncbi request reprint A review of atomoxetine effects in young people with developmental disabilities
    Michael G Aman
    The Nisonger Center UCEDD, Ohio State University, McCampbell Hall, 1581 Dodd Dr, Columbus, OH 43210, United States Electronic address
    Res Dev Disabil 35:1412-24. 2014
  3. pmc What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?
    Michael G Aman
    The Ohio State University Electronic address
    J Am Acad Child Adolesc Psychiatry 53:47-60.e1. 2014
  4. ncbi request reprint Pharmacotherapy of disorders in mental retardation
    M G Aman
    The Nisonger Center for Mental Retardation and Developmental Disabilities, Ohio State University, Columbus 43210 1296, USA
    Eur Child Adolesc Psychiatry 9:I98-107. 2000
  5. ncbi request reprint Acute and long-term safety and tolerability of risperidone in children with autism
    Michael G Aman
    The Nisonger Center, Ohio State University, Columbus, Ohio 43210 1296, USA
    J Child Adolesc Psychopharmacol 15:869-84. 2005
  6. ncbi request reprint The Nisonger Child Behavior Rating Form: typical IQ version
    Michael Aman
    The Nisonger Center, Ohio State University, Columbus, OH 43210 1296, USA
    Int Clin Psychopharmacol 23:232-42. 2008
  7. ncbi request reprint Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone
    Michael G Aman
    Nisonger Center, Ohio State University, Columbus 43210 1257, USA
    J Clin Psychiatry 65:1197-210. 2004
  8. ncbi request reprint Project MED: effects of a Medication EDucation booklet series for individuals with intellectual disabilities
    Michael G Aman
    Ohio State University, Columbus, OH 43210 1296, USA
    Intellect Dev Disabil 45:33-45. 2007
  9. ncbi request reprint Medication patterns in patients with autism: temporal, regional, and demographic influences
    Michael G Aman
    The Nisonger Center, Ohio State University, Columbus, Ohio 43210 1257, USA
    J Child Adolesc Psychopharmacol 15:116-26. 2005
  10. ncbi request reprint Treatment planning for patients with autism spectrum disorders
    Michael G Aman
    The Nisonger Center, Ohio State University, Columbus, Ohio 43210 1296, USA
    J Clin Psychiatry 66:38-45. 2005

Research Grants

Detail Information

Publications61

  1. ncbi request reprint Outcome measures for clinical drug trials in autism
    Michael G Aman
    Department of Psychology, Nisonger Center, Ohio State University, Columbus 43210 1257, USA
    CNS Spectr 9:36-47. 2004
    ..It is often appropriate to include laboratory tests and assessments for continence and sleep pattern...
  2. ncbi request reprint A review of atomoxetine effects in young people with developmental disabilities
    Michael G Aman
    The Nisonger Center UCEDD, Ohio State University, McCampbell Hall, 1581 Dodd Dr, Columbus, OH 43210, United States Electronic address
    Res Dev Disabil 35:1412-24. 2014
    ..Splitting the dose initially, starting below the recommended starting dose, and titrating slowly may prevent or ameliorate side effects. Patience is needed for the slow build-up of benefit...
  3. pmc What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?
    Michael G Aman
    The Ohio State University Electronic address
    J Am Acad Child Adolesc Psychiatry 53:47-60.e1. 2014
    ..The value of adding risperidone to concurrent psychostimulant and parent training (PT) in behavior management for children with severe aggression was tested...
  4. ncbi request reprint Pharmacotherapy of disorders in mental retardation
    M G Aman
    The Nisonger Center for Mental Retardation and Developmental Disabilities, Ohio State University, Columbus 43210 1296, USA
    Eur Child Adolesc Psychiatry 9:I98-107. 2000
    ..The best policy is probably to treat such patients cautiously, while gathering data on the effects of such therapy in the hopes of beginning a data base...
  5. ncbi request reprint Acute and long-term safety and tolerability of risperidone in children with autism
    Michael G Aman
    The Nisonger Center, Ohio State University, Columbus, Ohio 43210 1296, USA
    J Child Adolesc Psychopharmacol 15:869-84. 2005
    ..Most AEs were mild to moderate and failed to interfere with therapeutic changes; there were no unanticipated AEs. The side effects of most concern were somnolence and weight gain...
  6. ncbi request reprint The Nisonger Child Behavior Rating Form: typical IQ version
    Michael Aman
    The Nisonger Center, Ohio State University, Columbus, OH 43210 1296, USA
    Int Clin Psychopharmacol 23:232-42. 2008
    ..Like its predecessor, the NCBRF-TIQ (for typical IQ) is in the public domain and is available free to researchers and clinicians for assessment and treatment...
  7. ncbi request reprint Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone
    Michael G Aman
    Nisonger Center, Ohio State University, Columbus 43210 1257, USA
    J Clin Psychiatry 65:1197-210. 2004
    ....
  8. ncbi request reprint Project MED: effects of a Medication EDucation booklet series for individuals with intellectual disabilities
    Michael G Aman
    Ohio State University, Columbus, OH 43210 1296, USA
    Intellect Dev Disabil 45:33-45. 2007
    ..Female and minority respondents indicated somewhat higher satisfaction with the booklets than did their counterparts...
  9. ncbi request reprint Medication patterns in patients with autism: temporal, regional, and demographic influences
    Michael G Aman
    The Nisonger Center, Ohio State University, Columbus, Ohio 43210 1257, USA
    J Child Adolesc Psychopharmacol 15:116-26. 2005
    ..Greater age and handicap, and more restrictive placements, were associated with the use of several drug classes. Knowledge of these patterns may help families and medical planners anticipate future needs...
  10. ncbi request reprint Treatment planning for patients with autism spectrum disorders
    Michael G Aman
    The Nisonger Center, Ohio State University, Columbus, Ohio 43210 1296, USA
    J Clin Psychiatry 66:38-45. 2005
    ....
  11. ncbi request reprint Pharmacotherapy of disruptive behavior and item changes on a standardized rating scale: pooled analysis of risperidone effects in children with subaverage IQ
    Michael Aman
    The Nisonger Center, Ohio State University, Columbus, Ohio 4310, USA
    J Child Adolesc Psychopharmacol 15:220-32. 2005
    ..The aim of this study was to determine the effect of risperidone in a clinical setting on the symptom items of the Nisonger Child Behavior Rating Form (N-CBRF), used for the assessment of DBD patients...
  12. pmc Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders
    Michael G Aman
    Department of Psychology, Ohio State University, 225 Psychology Building, 1835 Neil Avenue, Columbus, OH 43210, USA
    Child Adolesc Psychiatr Clin N Am 17:713-38, vii. 2008
    ..Evidence for efficacy seems weakest for newer antidepressants, anxiolytics, and mood stabilizers...
  13. ncbi request reprint Four-year follow-up of children with low intelligence and ADHD: a replication
    Michael G Aman
    The Nisonger Center, The Ohio State University, Columbus 43210 2157, USA
    Res Dev Disabil 23:119-34. 2002
    ..Ratings on the ABC by parents and teachers showed significantly lower scores at follow-up on the Hyperactivity subscale. Relatively few associations were found between initial ratings and follow-up ratings on standardized scales...
  14. pmc Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders
    Michael G Aman
    The Nisonger Center, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Ther 29:1476-86. 2007
    ..Risperidone is probably the most frequently used atypical antipsychotic in the pediatric population...
  15. pmc Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial
    Michael G Aman
    The Nisonger Center UCEDD, Ohio State University, Columbus, OH 43210 1257, USA
    J Am Acad Child Adolesc Psychiatry 48:1143-54. 2009
    ..We tested whether combined treatment (COMB) with risperidone and parent training (PT) in behavior management is superior to medication alone (MED) in improving severe behavioral problems in children with PDDs...
  16. ncbi request reprint Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder
    Michael G Aman
    The Nisonger Center, The Ohio State University, Columbus, Ohio 43210, USA
    J Child Adolesc Psychopharmacol 20:415-22. 2010
    ..The aim of this study was to evaluate the efficacy of aripiprazole in the treatment of discrete symptoms of irritability associated with autistic disorder, as well as other symptoms captured on the Aberrant Behavior Checklist (ABC)...
  17. ncbi request reprint Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence
    Michael G Aman
    Nisonger Center UAP, Ohio State University, Columbus 43210 1257, USA
    Am J Psychiatry 159:1337-46. 2002
    ..The short-term efficacy and safety of risperidone in the treatment of disruptive behaviors was examined in a well-characterized cohort of children with subaverage intelligence...
  18. ncbi request reprint Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ
    Michael G Aman
    The Nisonger Center, Ohio State University, 1581 Dodd Drive, Columbus, OH 43210 1257, USA
    J Child Adolesc Psychopharmacol 14:243-54. 2004
    ....
  19. ncbi request reprint Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder
    Michael G Aman
    Nisonger Center, Ohio State University, Columbus, OH 43210 1296, USA
    Semin Pediatr Neurol 11:225-8. 2004
    ..More research is needed on the management of all of these target symptoms, both for new agents (e.g., atomoxetine) and for established psychoactive medicines...
  20. pmc Cognitive effects of risperidone in children with autism and irritable behavior
    Michael G Aman
    Nisonger Center, Ohio State University, Columbus, OH, USA
    J Child Adolesc Psychopharmacol 18:227-36. 2008
    ..The objective of this research was to explore the effects of risperidone on cognitive processes in children with autism and irritable behavior...
  21. ncbi request reprint Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial
    L Eugene Arnold
    The authors are with Ohio State University s Nisonger Center, Columbus, OH 43210, USA
    J Am Acad Child Adolesc Psychiatry 45:1196-205. 2006
    ..To explore placebo-controlled efficacy and safety of atomoxetine (ATX) for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorders (ASD)...
  22. ncbi request reprint Validity of the autism diagnostic interview-revised
    Luc Lecavalier
    Nisonger Center, The Ohio State University, Columbus, USA
    Am J Ment Retard 111:199-215. 2006
    ..They indicated some similarities between constructs, but also that the ADI-R measures autism in a unique fashion...
  23. pmc Aripiprazole for the treatment of irritability associated with autism
    Cristan Ann Farmer
    The Ohio State University, Nisonger Center, 1581 Dodd Drive, Columbus, OH 43210, USA
    Expert Opin Pharmacother 12:635-40. 2011
    ..Although multiple agents have been found to be effective, the safety and tolerability of each antipsychotic may be the determining factor in its selection...
  24. doi request reprint Psychometric properties of the Children's Scale of Hostility and Aggression: Reactive/Proactive (C-SHARP)
    Cristan A Farmer
    Nisonger Center, Ohio State University, Columbus, OH 43210, USA
    Res Dev Disabil 31:270-80. 2010
    ..The C-SHARP appears to have fundamentally sound psychometric characteristics, although more research is needed...
  25. ncbi request reprint Development of the Children's Scale of Hostility and Aggression: Reactive/Proactive (C-SHARP)
    Cristan A Farmer
    Ohio State University Nisonger Center, Columbus, OH 43210, USA
    Res Dev Disabil 30:1155-67. 2009
    ..General validity was supported by expected differences between age and gender groups. Preliminary normative data were presented. The C-SHARP appears to be a promising tool for assessing aggression and hostility in children with DD...
  26. pmc Behavioral assessment of impulsivity: a comparison of children with and without attention deficit hyperactivity disorder
    Nancy A Neef
    The Ohio State University, College of Education, Columbus 43210, USA
    J Appl Behav Anal 38:23-37. 2005
    ..Results are discussed with respect to the implications for assessment and treatment of ADHD...
  27. doi request reprint Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children
    Michael G Aman
    The Ohio State University, USA
    Res Dev Disabil 30:386-96. 2009
    ..02, eta(P)(2)=0.36) occurred in the risperidone condition. The findings suggest a beneficial effect of risperidone after several months of treatment on efficiency of responding, activity level, static tremor, and aspects of behavior...
  28. pmc Evaluation of pharmacological treatment of impulsivity in children with attention deficit hyperactivity disorder
    Nancy A Neef
    College of Education, The Ohio State University, 1945 N High St, 367 Arps Hall, Columbus, Ohio 43210, USA
    J Appl Behav Anal 38:135-46. 2005
    ..Reinforcer immediacy was the most influential dimension for 3 of the students and the second most influential dimension for 1 of the students across placebo and medication conditions; medication did not affect these sensitivities...
  29. ncbi request reprint Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies
    Michael G Aman
    Department of Psychiatry, School of Medicine, University of Auckland, Auckland, New Zealand
    J Child Adolesc Psychopharmacol 13:29-40. 2003
    ..To determine response of low-IQ children with attention deficit hyperactivity disorder (ADHD) symptoms to methylphenidate (MPH)...
  30. ncbi request reprint Reliability and validity of an assessment instrument for anxiety, depression, and mood among individuals with mental retardation
    Anna J Esbensen
    The Ohio State University, Columbus, Ohio 43210, USA
    J Autism Dev Disord 33:617-29. 2003
    ..The ADAMS appears to be a psychometrically sound instrument for screening anxiety, depression and mood disorders among individuals with mental retardation...
  31. ncbi request reprint Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials
    L Eugene Arnold
    Ohio State University, 479 S Galena Road, Sunbury, OH 43074, USA
    J Am Acad Child Adolesc Psychiatry 42:1443-50. 2003
    ..A consumer-oriented efficacy assessment in clinical trials should measure changes in chief complaint and consumer request (symptoms of most concern to patient/caregiver), which may be diluted in change scores of multisymptom scales...
  32. doi request reprint Development of the Adult Scale of Hostility and Aggression: Reactive-Proactive (A-SHARP)
    Scott Thomas Matlock
    Department of Psychology, The Ohio State University, Columbus, OH 43210, USA
    Am J Intellect Dev Disabil 116:130-41. 2011
    ..proactive). Analyses of demographic variables revealed 1 gender effect, several effects due to age and functional level, and no effect of ethnicity. Normative data are provided for the Problem Scale...
  33. doi request reprint Pharmacological treatment of sleep disturbance in developmental disabilities: a review of the literature
    Jill A Hollway
    The Nisonger Center UCEDD, The Ohio State University, I DD Psychology, 1581 Dodd Drive, Columbus, OH 43210, United States
    Res Dev Disabil 32:939-62. 2011
    ..Melatonin appears to be the most widely assessed agent and safest choice for children with developmental disabilities. Trazodone, mirtazapine, and ramelteon hold promise but require further study...
  34. ncbi request reprint Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education
    Elaine C Brown
    The Nisonger Center for Mental Retardation and Developmental Disabilities, The Ohio State University, Columbus 43210 1296, USA
    Res Dev Disabil 23:45-60. 2002
    ..With some qualifications, the ABC-C appears to be valid for assessing children in special educational settings, although further research is needed on the ABC's factor structure in this population...
  35. ncbi request reprint Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina
    Kristen S Langworthy-Lam
    The Nisonger Center for Mental Retardation and Developmental Disabilities, The Ohio State University, Columus, Ohio 43210, USA
    J Child Adolesc Psychopharmacol 12:311-21. 2002
    ..These findings suggest that individuals with autism are a frequently medicated group, although the empirical research support for most agents being used is still very limited...
  36. ncbi request reprint Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders
    Ronald L Lindsay
    The Nisonger Center for Mental Retardation, Ohio State University, Columbus, Ohio, USA
    Clin Pediatr (Phila) 43:437-44. 2004
    ..The authors provide several recommendations for clinicians and researchers working with atypical antipsychotics...
  37. ncbi request reprint Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio
    Michael G Aman
    The Nisonger Center for Mental Retardation and Developmental Disabilities, The Ohio State University, 1581 Dodd Drive, Columbus, OH 43210 1296, USA
    J Autism Dev Disord 33:527-34. 2003
    ..OTC autism preparations were used in substantial numbers of individuals, despite limited research support and the possibility of toxic effects...
  38. ncbi request reprint Factor analysis of the Nisonger Child Behavior Rating Form in children with autism spectrum disorders
    Luc Lecavalier
    Department of Psychology and Nisonger Centre, The Ohio State University, Columbus, Ohio 43210 1257, USA
    J Autism Dev Disord 34:709-21. 2004
    ..Confirmatory factor analyses indicated good fits for the social competence items and acceptable fits for the problem behavior items. Overall, results supported the construct validity of the NCBRF in children and adolescents with ASDs...
  39. pmc Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability
    L Eugene Arnold
    Department of Psychiatry, Ohio State University, Columbus, Ohio, USA
    J Child Adolesc Psychopharmacol 20:83-93. 2010
    ..2 in favor of risperidone on the main outcome measure in an 8-week double-blind, placebo-controlled trial for irritability in autistic disorder. This paper explores moderators and mediators of this effect...
  40. ncbi request reprint Pharmacologic therapies aid treatment for autism
    Ronald L Lindsay
    Arizona Child Study Center, Phoenix, USA
    Pediatr Ann 32:671-6. 2003
    ..Further well-designed double-blind studies with significant numbers of subjects and defined target symptoms will provide the data that will guide therapeutic decisions in the future...
  41. ncbi request reprint Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ
    Robert L Findling
    Department of Psychiatry, Case Western Reserve University, University Hospital of Cleveland, OH 44106, USA
    Am J Psychiatry 161:677-84. 2004
    ..This study determined the long-term safety and effectiveness of risperidone in treating severe disruptive behavior in children with subaverage intelligence...
  42. ncbi request reprint Impact of recent findings on study design of future autism clinical trials
    Eric Hollander
    Department of Psychiatry, Mount Sinai School of Medicine, New York City, New York 10029 6574, USA
    CNS Spectr 9:49-56. 2004
    ..The Internet System for Assessing Autistic Children system for managing multicenter clinical trials in autism and statistical issues in autism research are also described...
  43. ncbi request reprint Risperidone in children with autism and serious behavioral problems
    James T McCracken
    University of California, Los Angeles, USA
    N Engl J Med 347:314-21. 2002
    ..However, data on the safety and efficacy of atypical antipsychotic agents in children are limited...
  44. ncbi request reprint Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning
    Denis G Sukhodolsky
    The Child Study Center, Yale University, 230 South Frontage Road, New Haven, CT 06520, USA
    J Abnorm Child Psychol 36:117-28. 2008
    ..Limited data are available on the prevalence of anxiety in these children. We examined frequency and correlates of parent-rated anxiety symptoms in a large sample of children with PDD...
  45. ncbi request reprint Empirical classification of behavioral and psychiatric problems in children and adolescents with mental retardation
    Elaine C Brown
    Sierra Regional Center, Sparks, Nevada, USA
    Am J Ment Retard 109:445-55. 2004
    ..The external data provided modest to strong support for all except one cluster (Social Withdrawal With Agitation)...
  46. ncbi request reprint Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies
    Peter S Jensen
    Center for the Advancement of Children s Mental Health, Columbia University NYSPI 1051 Riverside Drive, Unit 78, New York, NY 10032, USA
    J Am Acad Child Adolesc Psychiatry 46:309-22. 2007
    ..If so, how should IA be assessed, pharmacological studies designed, and ethical issues addressed?..
  47. ncbi request reprint Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology
    Christopher J McDougle
    Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202 4800, USA
    Am J Psychiatry 162:1142-8. 2005
    ..The authors report on whether risperidone improves the core symptoms of autism, social and communication impairment and repetitive and stereotyped behavior...
  48. ncbi request reprint Research knowledge among parents of children participating in a randomized clinical trial
    Benedetto Vitiello
    Child and Adolescent Treatment and Preventive Intervention Research Branch, National Institute of Mental Health, Bethesda, MD 20892 9633, USA
    J Am Acad Child Adolesc Psychiatry 44:145-9. 2005
    ..Parental permission is required for child research, but parents' understanding of research aims and procedures has not been well documented. Parental research knowledge was assessed during a clinical trial in autism...
  49. ncbi request reprint Risperidone and adaptive behavior in children with autism
    Susan K Williams
    Yale University, New Haven, CT 06520 7900, USA
    J Am Acad Child Adolesc Psychiatry 45:431-9. 2006
    ..To evaluate the impact of risperidone on adaptive behavior in children with autistic disorder who have serious behavior problems and to examine different methods of scoring the Vineland Adaptive Behavior Scales to measure change...
  50. ncbi request reprint Effects of short- and long-term risperidone treatment on prolactin levels in children with autism
    George M Anderson
    Child Study Center, Yale University School of Medicine, New Haven, Connecticut, USA
    Biol Psychiatry 61:545-50. 2007
    ..The effects of short- and long-term risperidone treatment on serum prolactin were assessed in children and adolescents with autism...
  51. ncbi request reprint Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders
    Lawrence Scahill
    Yale Child Study Center, Yale University, New Haven, CT 06520, USA
    J Am Acad Child Adolesc Psychiatry 45:1114-23. 2006
    ..To examine the psychometric properties of the Children's Yale-Brown Obsessive Compulsive Scales (CYBOCS) modified for pervasive developmental disorders (PDDs)...
  52. ncbi request reprint Risperidone in the management of disruptive behavior disorders
    Gahan J Pandina
    Medical Affairs Division, Janssen Pharmaceutica Products, L P, Titusville, New Jersey, USA
    J Child Adolesc Psychopharmacol 16:379-92. 2006
    ..As with all antipsychotics, practitioners should monitor young patients' growth, weight, sexual maturation, and metabolic parameters...
  53. ncbi request reprint The Repetitive Behavior Scale-Revised: independent validation in individuals with autism spectrum disorders
    Kristen S L Lam
    Neurodevelopmental Disorders Research Center, University of North Carolina at Chapel Hill, CB 3367, Chapel Hill, NC 27599 3367, USA
    J Autism Dev Disord 37:855-66. 2007
    ..Measures of internal consistency were high for this solution, and interrater reliability data suggested that the RBS-R performs well in outpatient settings...
  54. ncbi request reprint A prospective open trial of guanfacine in children with pervasive developmental disorders
    Lawrence Scahill
    Yale Child Study Center, P O Box 207900, New Haven, CT 06520, USA
    J Child Adolesc Psychopharmacol 16:589-98. 2006
    ..A common complaint for children with pervasive developmental disorder (PDD) is hyperactivity. The purpose of this pilot study was to gather preliminary information on the efficacy of guanfacine in children with PDD and hyperactivity...
  55. ncbi request reprint Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study
    Ronald L Lindsay
    Children s Health Center of St Joseph s Hospital and Medical Center, Arizona 85013, USA
    J Intellect Dev Disabil 31:204-9. 2006
    ..Risperidone may be effective in improving tantrums, aggression, or self-injurious behaviour in children with autism, but often leads to weight gain...
  56. ncbi request reprint Risperidone and cognitive function in children with disruptive behavior disorders
    Gahan J Pandina
    Medical Affairs, Janssen Pharmaceutica, Inc, Titusville, New Jersey 08560, USA
    Biol Psychiatry 62:226-34. 2007
    ..Effects of risperidone on cognitive function in children with disruptive behavior disorders (DBDs) and subaverage intelligence quotient (IQ) were assessed...
  57. pmc Developmental disabilities modification of the Children's Global Assessment Scale
    Ann Wagner
    National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
    Biol Psychiatry 61:504-11. 2007
    ..To measure global functioning in treatment studies, the Children's Global Assessment Scale was modified and psychometric properties of the revised version (DD-CGAS) were assessed in children with PDD...
  58. ncbi request reprint Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures
    David J Posey
    Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Biol Psychiatry 61:538-44. 2007
    ....
  59. ncbi request reprint Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials
    John C LeBlanc
    Department of Pediatrics, Psychiatry, Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada
    Int Clin Psychopharmacol 20:275-83. 2005
    ..6; mean endpoint AS 8.3; 21.7% reduction). Risperidone was efficacious in reducing symptoms of aggression in boys of below average IQ with disruptive behaviour disorders...
  60. ncbi request reprint The Aberrant Behavior Checklist and the Behavior Problems Inventory: convergent and divergent validity
    Johannes Rojahn
    George Mason University, Center for Cognitive Development, 4400 University Drive, MSN 2C6, Fairfax, VA 22030, USA
    Res Dev Disabil 24:391-404. 2003
    ..Thus, the ABC and the BPI cross-validated one another where expected, and they diverged for subscales thought to have little relationship...
  61. ncbi request reprint Neurochemical correlates of autistic disorder: a review of the literature
    Kristen S L Lam
    Neurodevelopmental Disorders Research Center, University of North Carolina at Chapel Hill, USA
    Res Dev Disabil 27:254-89. 2006
    ..In addition, research in neurochemistry must continue to work in concert with other subspecialties to form a more comprehensive and theory-based approach to the neurobiological correlates of autistic disorder...

Research Grants9

  1. RUPP-PI Project
    Michael Aman; Fiscal Year: 2002
    ..S.U. also plans two pilot studies: (a) a randomized clinical trial in 60 children with PDDs and severe ADHD behavior and (b) a study of ziprasidone in 30 children and adolescents with PDDs and highly irritable behaviors. ..
  2. RUPP-PI Project
    Michael Aman; Fiscal Year: 2006
    ..S.U. also plans two pilot studies: (a) a randomized clinical trial in 60 children with PDDs and severe ADHD behavior and (b) a study of ziprasidone in 30 children and adolescents with PDDs and highly irritable behaviors. ..
  3. 2/3-Atomoxetine Placebo and Parent Training in Autism
    Michael Aman; Fiscal Year: 2009
    ..This trial has the potential to provide answers regarding optimal treatment (both psychosocial and pharmacological) for a sizeable subgroup of children with ASD who experience symptoms of over activity and inattention. ..
  4. 1/4-Stimulant and Risperidone for Youth with Severe Physical Aggression
    Michael Aman; Fiscal Year: 2009
    ..Given the increasing rates and severity of violence in our society, this investigation will help to determine if drug therapy, combined with parent-provided behavior therapy, can reduce child aggression. ..
  5. 1/4-Stimulant and Risperidone for Youth with Severe Physical Aggression
    MICHAEL GEORGE AMAN; Fiscal Year: 2010
    ..Given the increasing rates and severity of violence in our society, this investigation will help to determine if drug therapy, combined with parent-provided behavior therapy, can reduce child aggression. ..
  6. 1/4-Stimulant and Risperidone for Youth with Severe Physical Aggression
    Michael Aman; Fiscal Year: 2009
    ..Given the increasing rates and severity of violence in our society, this investigation will help to determine if drug therapy, combined with parent-provided behavior therapy, can reduce child aggression. ..
  7. 2/3-Atomoxetine Placebo and Parent Training in Autism
    MICHAEL GEORGE AMAN; Fiscal Year: 2010
    ..This trial has the potential to provide answers regarding optimal treatment (both psychosocial and pharmacological) for a sizeable subgroup of children with ASD who experience symptoms of over activity and inattention. ..